A Study Assessing B-VEC Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa (IOLITE)

Krystal Biotech

Status and phase: Enrolling; Phase 3

Conditions: DEB - Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; Dystrophic Epidermolysis Bullosa

Treatments: Biological: Ophthalmic Beremagene Geperpavec (B-VEC); Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT07016750

B-VEC-EYE-01

Details and patient eligibility

About

B-VEC-EYE-01 is a Phase 3 double-blind, intra-patient crossover study, to evaluate the safety and efficacy of ophthalmic Beremagene Geperpavec (B-VEC) versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).

Full description

Subjects participating in the Sponsor's natural history study (protocol B-VEC-EYE-NHS) for at least 12 weeks and that meet all other eligibility criteria receive weekly ophthalmic administration of Investigational product (IP), B-VEC or placebo, for the first 12-week intervention period. During the second intervention period subjects will receive the alternative IP for an additional 12 weeks. IP will be administered in the home setting by a healthcare provider. The Investigator (or designee) will contact subjects (or their parent/legal guardian) to assess for any adverse events or changes in medications, treatments, or procedures. Subjects (or their parent/legal guardian) will complete weekly symptom diaries and monthly questionnaires to document corneal abrasion symptoms and frequency and gauge overall subject (or parent/legal guardian) impressions of disease severity and disease/symptom changes during the study.

Enrollment: 16 estimated patients

Sex: All

Ages: 6+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The subject and/or their parent/legal guardian must provide informed consent/assent and must be able to and willing to follow study procedures and instructions.
2. Age 6 months or older at time of informed consent/assent.
3. Confirmed diagnosis of DEB with a mutation in the COL7A1 gene.
4. Meets minimum corneal abrasion symptom frequency in the B-VEC-EYE-NHS study.

Exclusion criteria

1. Initiation of any new treatment regimen or change in treatment for ocular disease during the run-in period except for preservative free topical antibiotics or artificial tears/lubricants associated with standard of care treatment of corneal abrasions.
2. Treatment with an investigational agent or off-label ophthalmic use of an approved product during the run-in period or planned use during the study (Exceptions may be approved by the medical monitor on a case-by-case basis).
3. Any condition that, in the opinion of the Investigator, would impact the completion of all study-related assessments, interfere with the administration of study drug, and/or poses an additional risk to the subject.
4. Women who are pregnant or nursing.
5. Subject who is unwilling to comply with contraception requirements per protocol.
6. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the Investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

16 participants in 2 patient groups, including a placebo group

B-VEC

Experimental group

Description:

B-VEC

Treatment:

Biological: Ophthalmic Beremagene Geperpavec (B-VEC)

Placebo

Placebo Comparator group

Description:

Vehicle

Treatment:

Drug: Placebo